CLEVIPREX® (clevidipine) is RECOMMENDED IN THE 2018 AHA/ASA AIS GUIDELINES^1*

Since 2018, the Guidelines for the Early Management of Patients With Acute Ischemic Stroke (AIS) have recommended CLEVIPREX as an option for lowering arterial hypertension before, during, and after acute reperfusion therapy.^1*

For an AIS patient who is otherwise eligible for acute reperfusion therapy except that BP is >185/110 mm Hg

Treatment options^†

Clevidipine 1–2 mg/h IV, titrate by doubling the dose every 2 to 5 minutes until desired BP reached; maximum 21 mg/h; or

Labetalol 10–20 mg IV over 1 to 2 minutes, may repeat 1 time; or

Nicardipine 5 mg/h IV, titrate up by 2.5 mg/h every 5 to 15 minutes, maximum 15 mg/h; when desired BP reached, adjust to maintain proper BP limit

Other agents (eg, hydralazine, enalaprilat) may also be considered

For an AIS patient who has either SBP >180–230 mm Hg or DBP >105–120 mm Hg

Treatment options^†

Clevidipine 1–2 mg/h IV, titrate by doubling the dose every 2 to 5 minutes until desired BP reached; maximum 21 mg/h; or

Labetalol 10 mg IV followed by continuous IV infusion
2–8 mg/min; or

Nicardipine 5 mg/h IV, titrate up to desired effect by 2.5 mg/h every 5 to 15 minutes, maximum 15 mg/h

If BP not controlled or DBP >140 mm Hg, consider IV sodium nitroprusside

*Recommendation Class IIb (benefit ≥ risk); Level of Evidence C-EO (consensus of expert opinion based on clinical experience).

^†Different treatment options may be appropriate in patients who have comorbid conditions that may benefit from acute reductions in BP such as acute coronary event, acute heart failure, aortic dissection, or preeclampsia/eclampsia.

CLEVIPREX is not indicated for the prevention or treatment of stroke.